Agios Pharmaceuticals | AGIO - Current Liabilities


Agios Pharmaceuticals reported $74.76M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Arrowhead Research USD 195.49M 957K Sep/2025
Astellas Pharma JPY 1.33T 217.52B Sep/2025
AstraZeneca USD 34.05B 518M Sep/2025
Bayer EUR 28.96B 825M Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Exelixis USD 373.78M 37.67M Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
GlaxoSmithKline GBP 21.33B 956M Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.68B 109M Sep/2025
Novartis USD 32B 286M Sep/2025
Novartis USD 32B 286M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025